Targeted delivery of them to cancer cells can efficiently amplify systemic anti-tumor immunity by reversing immunosuppressive TME and triggering a cascade of proinflammatory events.704,705 However, the studies focusing on the application of oncolytic virotherapies functioning in a TRIC-activating/inactivating manner for cancer treatment are few. Here, MARVELD2 is linked to cancer.